Recommended dosing conversions for anticoagulants such as warfarin, heparin, and dabigatran.
A comparative medication chart of thromboembolic disorder treatments in patients without DVT/PE.
The FDA has approved Ultomiris (ravulizumab-cwvz; Alexion) for the treatment of atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA) in adult and pediatric patients aged 1 month and older.
Results from a new real-world study evaluating rivaroxaban (Xarelto; Janssen), a factor Xa inhibitor, in morbidly obese patients were recently published in Thrombosis Research. The retrospective cohort study analyzed data from 2 US claims databases (Truven MarketScan Commercial Claims and Encounters database and MarketScan Medicare Supplemental database) to evaluate the clinical and health/economic outcomes of…
Results of the study showed that the rate of symptomatic recurrent VTE – the primary end point – was similar in both treatment groups with 1.2% of patients experiencing a recurrent event in the rivaroxaban group compared with 3.0% in the standard anticoagulation group.
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to PB2452 (PhaseBio), an investigational reversal agent for ticagrelor.